Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Peristeri – page 86

1 033 clinical trials in Peristeri, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Peristeri at a glance
1 033
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 033 trials in Peristeri

Open in trial search

Study on Golexanolone for Patients with Primary Biliary Cholangitis Experiencing Fatigue and Cognitive Dysfunction

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Golexanolone
  • Sponsor:Umecrine Cognition AB

Sepsis

Not recruiting

Study on Emapalumab for Patients with Sepsis Linked to Interferon-Gamma

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Emapalumab
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Pemphigoid

Not recruiting

Study on Long-term Safety and Effects of Efgartigimod PH20 SC for Adults with Bullous Pemphigoid

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Cardiac failure+4

Not recruiting

Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:CDR132L
  • Sponsor:Cardior Pharmaceuticals GmbH

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Gilead Sciences Inc.

Study on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Primary amyloidosis

Not recruiting

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Birtamimab
  • Sponsor:Prothena Biosciences Limited

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Peristeri

What the registry says about research in the country

01 Cardiovascular Diseases

In Peristeri, researchers are evaluating a weekly injectable agent for patients with HFpEF or HFmrEF who also have obesity, aiming to lower the combined risk of cardiovascular death and heart‑failure hospitalisations.

  • Composite cardiovascular outcome assessment
  • Weekly dosing strategy
  • Integration with standard of care
  • Focus on heart‑failure subtypes

Both studies are actively recruiting, involve 25 investigators, and seek to improve treatment options for a growing heart‑failure population.

02 Nutritional and Metabolic Diseases

Clinical trials in the city are comparing two formulations of injectable cagrilintide and a placebo, as adjuncts to diet and activity counseling, to achieve meaningful weight loss in participants with excess body weight.

  • Weight‑loss non‑inferiority testing
  • Superiority versus placebo evaluation
  • Adjunct lifestyle intervention
  • Targeting overweight and obesity

The recruiting studies involve a dedicated team of investigators and aim to expand therapeutic options for metabolic health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.